Putting Patients First

Each and every person in our trials plays a powerful role. We are grateful to the patients and families who have participated in our previous and ongoing clinical studies. We work diligently to protect their privacy, dignity, safety and well-being at all times.

Advancing Clinical Research

At I-Mab, we strive to develop innovative treatments for people with serious blood disorders and cancers.

Company Sponsored Trials

To make progress against cancer possible, we are currently conducting clinical studies globally to test the safety and efficacy of our potential new medicines.

Biomarker Research

Providing the right medicine to the right patient is central to I-Mab’s innovation. Throughout our clinical studies, we create and test approaches to select patients most likely to benefit, to support dose selection, and to enable informed decisions on advancing our therapies to the next phase of testing.

Investigator Sponsored Trials

Consistent with our commitment to scientific innovation and improving patient’s lives, we may provide support for independent investigators to expand scientific knowledge of our treatments by leading their own research projects using our therapies.

Selected Ongoing
Clinical Trials

Browse from our list of key clinical trials

Explore here to view our other studies, including studies that our partners are conducting in collaboration with us

Felzartamab TJ202

  • Phase 3
  • Multiple Myeloma

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Learn more at clinicaltrials.gov

Lemzoparlimab TJC4

  • Phase 2
  • MDS, AML

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Learn more at clinicaltrials.gov

Lemzoparlimab TJC4

  • Phase 2
  • Solid Tumors

A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Learn more at clinicaltrials.gov

Uliledlimab TJD5

  • Phase 2
  • Solid Tumors

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Learn more at clinicaltrials.gov

Efineptakin Alfa TJ107

  • Phase 2
  • TNBC, HNC

Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Learn more at clinicaltrials.gov

TJ-CD4B

  • Phase 1
  • Solid Tumors

Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors

Learn more at clinicaltrials.gov